COVID-19 Information Hub

Our response to COVID-19

The COVID-19 pandemic is a challenge to humanity that demands a global, united response, not just from the scientific community but also from industry, organisations, governments and every single person around the globe.

Since early 2020 when the true scale of the crisis became clear, AstraZeneca has committed to help defeat COVID-19 by harnessing and sharing our scientific knowledge and expertise to advance and accelerate the development of potential medicines to prevent or treat the virus.

We have donated nine million face masks to support healthcare workers in 49 countries, bolstered national COVID-19 testing effort and initiated clinical trials to investigate our new and existing medicines to see how they could treat the infection.

Recognising the urgent need for a vaccine to defeat the virus, we joined forces with the University of Oxford, bringing together its world-class expertise in vaccinology with our global development and manufacturing capabilities. We have accelerated clinical development and rapidly mobilised partnerships and a global supply chain that will support a broad, timely and equitable supply of a safe and effective vaccine around the world, if approved, and at no profit during the pandemic.

Complementing our vaccines approach, we also quickly mobilised research efforts to advance the development of a novel coronavirus-neutralising long-acting antibody combination (LAAB) for the potential prevention and treatment of COVID-19.

With the COVID-19 pandemic continuing to claim thousands of lives every day, we are moving quickly with our clinical trials while following strict regulatory standards, and good clinical practice and guided by robust independent data safety and monitoring boards. Given the unprecedented global impact of COVID-19 and the need for public information, we are committed to being transparent about this process.

Bolstered by our resiliency, our employees have maintained momentum, drawing motivation from our values to follow the science, do the right thing and put patients first.

Our priorities remain to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.

Latest news

Serum Institute of India obtains emergency use authorisation in India for AstraZeneca’s COVID-19 vaccine

6 January 2021

Corporate Press Release

AstraZeneca’s COVID-19 vaccine authorised for emergency supply in the UK

30 December 2020

Corporate Press Release

Update on application for conditional marketing authorisation for the AstraZeneca COVID-19 vaccine to the European Medicines Agency

30 December 2020

AZD1222 Oxford Phase III trials interim analysis results published in The Lancet

8 December 2020

Corporate Press Release

AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

23 November 2020

Corporate Press Release

FDA authorises restart of the COVID-19 AZD1222 vaccine US Phase III trial

23 October 2020

Corporate Press Release

COVID-19 Long-Acting AntiBody (LAAB) combination AZD7442 rapidly advances into Phase III clinical trials

9 October 2020

Corporate Press Release

COVID-19 vaccine AZD1222 clinical trial resumed in Japan, follows restart of trials in the UK, Brazil, South Africa and India

2 October 2020

Corporate Press Release

COVID-19 vaccine AZD1222 clinical trials resumed in the UK

12 September 2020

Corporate Press Release

Statement on AstraZeneca Oxford SARS-CoV-2 vaccine, AZD1222, COVID-19 vaccine trials temporary pause

9 September 2020

Corporate Press Release

Development of COVID-19 vaccine AZD1222 expands into US Phase III clinical trial across all adult age groups

31 August 2020

Corporate Press Release

AstraZeneca’s scientific and social commitment for COVID-19 vaccine

31 August 2020

Corporate Press Release

Phase I clinical trial initiated for monoclonal antibody combination for the prevention and treatment of COVID-19

25 August 2020

Corporate Press Release

AstraZeneca concludes agreement with the European Commission for the supply of up to 400 million doses of AZD1222 COVID-19 vaccine

14 August 2020

Corporate Press Release

COVID-19 vaccine AZD1222 showed robust immune responses in all participants in Phase I/II trial

20 July 2020

Corporate Press Release

AstraZeneca to supply Europe with up to 400 million doses of Oxford University’s vaccine at no profit

13 June 2020

Corporate Press Release

Calquence showed promising clinical improvement in majority of 19 hospitalised COVID-19 patients

5 June 2020

Corporate Press Release

AstraZeneca takes next steps towards broad and equitable access to Oxford University’s COVID-19 vaccine

4 June 2020

Corporate Press Release

AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford’s potential new vaccine

21 May 2020

Corporate Press Release

AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine

30 April 2020

Corporate Press Release

AstraZeneca joins UK Government’s ACCORD trial platform

28 April 2020

AZ and Saint Luke’s Mid America Heart Institute initiate Phase III DARE-19 trial with Farxiga in COVID-19 patients

23 April 2020

Corporate Press Release

AstraZeneca initiates CALAVI clinical trial with Calquence against COVID-19

14 April 2020

Corporate Press Release

AstraZeneca to donate 9 million face masks to support healthcare workers around the world in the fight against COVID-19

24 March 2020

Corporate Press Release

Latest articles

A vaccination program to meet the needs of a global pandemic

23 November 2020

What does immunogenicity mean in the context of COVID-19 vaccines?

19 November 2020

COVID-19 vaccine AZD1222 is better tolerated in older adults than younger adults with similar immune responses across all age groups

19 November 2020

Innovating Production and Manufacture to meet the Challenge of COVID-19

5 November 2020

How will COVID impact youth around the world long-term?

16 October 2020

New normal same cancer

7 October 2020

How the COVID-19 pandemic is changing the shape of cancer clinical trials

4 August 2020

Advancing our discovery of novel coronavirus-neutralising antibodies against COVID-19

9 June 2020

Planning for a sustainable future post-COVID-19

5 June 2020

Researching antibodies to target COVID-19

8 April 2020

Our priorities in responding to the COVID-19 outbreak

AstraZeneca is responding to the COVID-19 (novel coronavirus) outbreak, consistent with our values to follow the science, put patients first and do the right thing. Our priorities are to ensure the continued supply of our medicines to patients, and to safeguard the health and wellbeing of all our employees and communities.

13 March 2020

COVID-19 Frequently Asked Questions

For more information regarding AstraZeneca’s response to the COVID-19 pandemic, please visit our FAQ page.

View FAQs

Information for healthcare professionals

Healthcare providers

If you are a registered healthcare provider with questions about COVID-19 and AstraZeneca medications, please visit Astrazeneca's medical information websites at https://medicalinformation.astrazeneca.com/

https://medicalinformation.astrazeneca.com

COVID-19 clinical MDT experience sharing webcast

Leading experts share and discuss the latest scientific insights regarding COVID-19 disease development, as well as clinical experience in treating COVID-19 patients. This content is intended for HealthCare Professionals for medical educational purposes only.

https://covid19.astrazeneca.com

COVID-19 Employee & Leader Toolkits

COVID-19 Employee Toolkit

Created by subject matter experts from across AstraZeneca, this toolkit provides employees with advice and top tips on how to effectively navigate through COVID-19. The resource is available to everyone for external download.

PDF 7,293KB

COVID-19 Leader Toolkit

Created by subject matter experts from across AstraZeneca, this toolkit provides leaders with advice and top tips on how to effectively lead through COVID-19. The resource is available to everyone for external download.

PDF 6,836KB